Ignite Creation Date:
2025-12-24 @ 2:02 PM
Ignite Modification Date:
2026-05-22 @ 3:28 AM
Study NCT ID:
NCT03430895
Status:
COMPLETED
Last Update Posted:
2021-12-01
First Post:
2018-02-07
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
17-511
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |